• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccines (Basel) . The Highly Productive Thermothelomyces heterothallica C1 Expression System as a Host for Rapid Development of Influenza Vaccines

tetano

Editor, Senior Moderator
Vaccines (Basel)


. 2022 Jan 20;10(2):148.
doi: 10.3390/vaccines10020148.
The Highly Productive Thermothelomyces heterothallica C1 Expression System as a Host for Rapid Development of Influenza Vaccines


Gabor Keresztes[SUP] 1 [/SUP], Mark Baer[SUP] 2 [/SUP], Mark R Alfenito[SUP] 2 [/SUP], Theo C Verwoerd[SUP] 1 [/SUP], Andriy Kovalchuk[SUP] 3 [/SUP], Marilyn G Wiebe[SUP] 3 [/SUP], Tor Kristian Andersen[SUP] 4 [/SUP], Markku Saloheimo[SUP] 3 [/SUP], Ronen Tchelet[SUP] 1 [/SUP], Richard Kensinger[SUP] 5 [/SUP], Gunnveig Grødeland[SUP] 4 6 [/SUP], Mark Emalfarb[SUP] 1 [/SUP]



Affiliations
Free PMC article

Abstract

(1) Influenza viruses constantly change and evade prior immune responses, forcing seasonal re-vaccinations with updated vaccines. Current FDA-approved vaccine manufacturing technologies are too slow and/or expensive to quickly adapt to mid-season changes in the virus or to the emergence of pandemic strains. Therefore, cost-effective vaccine technologies that can quickly adapt to newly emerged strains are desirable. (2) The filamentous fungal host Thermothelomyces heterothallica C1 (C1, formerly Myceliophthora thermophila) offers a highly efficient and cost-effective alternative to reliably produce immunogens of vaccine quality at large scale. (3) We showed the utility of the C1 system expressing hemagglutinin (HA) and a HA fusion protein from different H1N1 influenza A virus strains. Mice vaccinated with the C1-derived HA proteins elicited anti-HA immune responses similar, or stronger than mice vaccinated with HA products derived from prototypical expression systems. A challenge study demonstrated that vaccinated mice were protected against the aggressive homologous viral challenge. (4) The C1 expression system is proposed as part of a set of protein expression systems for plug-and-play vaccine manufacturing platforms. Upon the emergence of pathogens of concern these platforms could serve as a quick solution for producing enough vaccines for immunizing the world population in a much shorter time and more affordably than is possible with current platforms.

Keywords: Thermothelomyces heterothallica C1; filamentous fungi; influenza vaccine; recombinant protein expression; targeted influenza hemagglutinin; trimeric influenza hemagglutinin.
 
Back
Top Bottom